YBL-006 is a monoclonal antibody discovered from our proprietary library that targets programmed cell death protein 1 (PD-1) and is currently undergoing Phase 1 clinical trials as a PD-1 immune checkpoint inhibitor.
The binding of PD-L1 and PD-L2 proteins on the surface of cancer cells to PD-1 proteins on the surface of T cells causes T cells to become unable to properly recognize the cancer cells and, therefore, not attack them.
YBL-006 is being developed independently by Y-Biologics, binding to PD-1 and inhibiting an immune escape mechanism of cancer cells.

준비중입니다.

LAG-3, which is expressed on activated T cells or regulatory T cells (Tregs) (CD4+ or CD8+), inhibits T cell activation by binding to MHC class II molecules or LSECtin, which are ligands present in antigen presenting cells (APCs) or cancer cells, thereby enabling the immune escape of cancer cells. YBL-011 targets LAG-3 on the surface of T cells and inhibits APCs or cancer cells from binding to MHC class II molecules, thereby enhancing T cell activity and suppressing Treg cell activity at the same time to kill cancer cells.

YBL-013 is a bispecific T-cell engager in our proprietary ALiCE format that simultaneously targets PD-L1 on tumor cells and CD3 on T cells. By binding CD3, YBL-013 is capable of redirecting T cells to the tumor and activating the T cells primarily at the tumor site to kill cancer cells. By targeting PD-L1 it is also capable of functioning as an immune checkpoint inhibitor and suppressing an immune escape mechanism used by cancer cells.

YBL-018은 와이바이오로직스가 개발한 Engager 플랫폼 형태를 가지고 있는 이중 항체입니다.
암세포의 표면에 있는 단백질인 B7-H3와 결합할 수 있는 항 B7-H3 재조합 단일사슬 부위와 T 세포의 표면에 있는 단백질인 CD3와
결합할 수 있는 항 CD3 재조합 단일사슬 부위로 이루어져 있으며, 암세포의 표적부위로 활성화된 T 세포를 끌어들여
T 세포에 의한 암세포의 사멸을 유도하는 기전을 가지고 있습니다.

YBL-001 is a Delta-like 1 homolog(DLK1)-targeting antibody-drug conjugate (DLK1-ADC) produced by conjugating an apoptotic payload to an antibody capable of being internalized and entering cells while binding specifically to DLK1 expressed in cancer cells. DLK1 has been observed to be overexpressed in patients with liver cancer, colorectal cancer, breast cancer, small cell lung cancer, and pancreatic islet cell tumors, and it is reported to be associated with cancer recurrence and metastasis as a cancer stem cell biomarker. YBL-001 can selectively kill DLK1-expressing cancer cells by specifically binding to DLK1, entering the cells, and releasing the conjugated toxic payload in the lysosome.

YBL-015 is an antibody drug conjugate that combines cytotoxic drugs with B7-H3 specific antibodies.B7-H3 is a new target of the Immune Checkpoint family.While the expression of B7-H3 in normal cells is very limited, it is known that it is prevalent in solid cancers including breasts, lungs, pancreas, prostate, kidneys, colon, skin, and brain. YBL-015 is a very specific antibody to B7-H3 and can selectively kill cancer cells in which B7-H3 is well expressed.

YBL-003, an antibody candidate for treatment of solid tumors, is a type of immune checkpoint inhibitor. It regulates the function of macrophages and T cell activity to reactivate the immune system in the tumor microenvironment and has a mechanism to kill cancer cells. Above all, the scope of the indications for YBL-008 can be expanded to include stomach cancer, lung cancer, breast cancer, and more, so it has high potential for use as an immuno-oncology agent targeting solid tumors.

준비중입니다.

YBL-034 is a double antibody targeting OX40L and TNF-a, which inhibits excessive activation of T-cells and simultaneously disrupts action of TNF-a, an inflammatory cytokine. This is an innovative pipeline that will satisfy the market's unmet demands as it is expected to get over the low reactivity of the existing treatments.

AR087 is an immune anticancer drug binding to immune-regulated target antigens expressed in cancer cells, causes immune cell activation, and kills cancer cells. Y Biologics plans to develop AR087 as a treatment for various solid cancers through joint researches with HK Innoen.